

# Neil Bayman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7064409/publications.pdf>

Version: 2024-02-01

11  
papers

279  
citations

1162367

8  
h-index

1473754

9  
g-index

11  
all docs

11  
docs citations

11  
times ranked

469  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prophylactic radiotherapy to intervention sites in mesothelioma: A systematic review and survey of UK practice. <i>Lung Cancer</i> , 2009, 66, 150-156.	0.9	58
2	Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 1200-1208.	0.8	52
3	New radiotherapy approaches in locally advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2014, 50, 525-534.	1.3	43
4	How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?. <i>Lung Cancer</i> , 2014, 83, 117-125.	0.9	35
5	Radiotherapy for lung cancer in the elderly. <i>Lung Cancer</i> , 2010, 68, 129-136.	0.9	34
6	Investigation of a Patient Reported Outcome tool to assess radiotherapy-related toxicity prospectively in patients with lung cancer. <i>Radiotherapy and Oncology</i> , 2014, 112, 244-249.	0.3	25
7	Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1341-1348.	0.4	17
8	Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?. <i>Lung Cancer</i> , 2018, 118, 139-147.	0.9	10
9	Impact of Introducing Intensity Modulated Radiotherapy on Curative Intent Radiotherapy and Survival for Lung Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
10	The use of volunteers to implement electronic patient reported outcomes in lung cancer outpatient clinics. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2018, 7, 11-16.	0.6	2
11	Reply to G. Zalcman et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 2694-2695.	0.8	0